Recently, the 2024 MENET Conference (China Medical and Health Industry Symbiosis Conference) hosted by the authoritative pharmaceutical information service platform MENet opened in Huzhou. At the meeting, the highly anticipated "2023 China Pharmaceutical Industry Top 100 Series List" was officially announced. Shanghai Huanghai Pharmaceutical Co., Ltd. (referred to as "Shanghai Huanghai Pharmaceutical"), a subsidiary of Shanghai Baiyang Pharmaceutical Co., Ltd. (referred to as "Baiyang Pharmaceutical"), was listed on the "2023 Chinese Medicine Enterprise TOP100" list with its strong research and development and production capabilities in modern Chinese medicine.

The list of China's Top 100 Pharmaceutical Industry focuses on the two dimensions of innovation driving force and professional promotion force of pharmaceutical industry enterprises. Based on its exclusive three terminal and six market terminal data for quantitative analysis, MineNet has finally selected five sub molecular lists, including the "TOP100 Chinese Medicine Enterprises" list. As an authoritative and representative selection activity in the pharmaceutical industry, this selection not only sets a benchmark for domestic pharmaceutical industry enterprises to enhance their comprehensive strength and expand brand effectiveness, but also showcases the outstanding style of pharmaceutical brand industry, guiding the stable, rapid and sustainable development of the pharmaceutical and health industry.

As a leading innovative traditional Chinese medicine and natural medicine national pharmaceutical enterprise under Baiyang Pharmaceutical, Shanghai Huanghai Pharmaceutical is committed to promoting the modernization of traditional Chinese medicine through technological innovation. Adhering to the concept of disease diagnosis, quality control, and proven efficacy, Shanghai Huanghai Pharmaceutical has established a modern, standardized, and international Chinese medicine research and development production system, and built a complete modern Chinese medicine industry chain that runs through medicinal herb cultivation and processing, Chinese medicine extraction to finished product formulation, and commercialization. In addition, Shanghai Huanghai Pharmaceutical has also passed multiple management system certifications and Shanghai's "Green Factory" certification, indicating that the company's professional capabilities in standardized, regulated, and refined management of production and operation have been widely recognized.

The independently developed new drugs with completely independent intellectual property rights, "Fuzheng Huayu Capsules (Tablets)" and "Qishe Pills", have won the second prize of National Science and Technology Progress Award for their related research. Among them, "Fuzheng Huayu Capsules (Tablets)", as an innovative traditional Chinese medicine product for treating liver fibrosis, has completed FDA Phase II clinical trials in the United States, ushering in a new era of antiviral and anti fibrotic "dual therapy" for liver disease. In the 20 years since its listing, Fuzheng Huayu has conducted 68 randomized controlled trials (RCTs) and participated in the National 12th Five Year Science and Technology Major Project, providing solid and reliable evidence-based medicine for reversing liver fibrosis/cirrhosis through in-depth and rigorous clinical research.

In addition to laying out modern traditional Chinese medicine, Shanghai Huanghai Pharmaceutical's parent company Baiyang Pharmaceutical also focuses on the research and production of high-end slow-release formulations such as osmotic pumps, pellet coatings, and skeleton tablets. The slow-release formulation research and production base located in Qingdao has repeatedly obtained the cGMP (Dynamic Good Manufacturing Practice) certification from the US FDA for "zero defects", and its products have achieved co production, reporting, and sales between China and the United States. Self developed and produced hypoglycemic drug metformin Nida ® For the infusion pump controlled release formulation of metformin, patients only need to take it once a day to achieve stable glycemic control, greatly improving medication adherence. Nida ® Approved for listing in the United States at the end of 2018 and achieved overseas sales the following year. Meanwhile, Nida ® It will also enter the national medical insurance drug catalog in 2023, achieving the domestic substitution of high-end preparations.

As a new force in Chinese national pharmaceuticals, Baiyang Pharmaceutical focuses on breakthroughs in the treatment gap of refractory diseases, continuously increasing research and development investment and innovation cooperation. The modern Chinese medicine R&D and production base located in Shanghai and the slow-release formulation R&D and production base located in Qingdao are undergoing pipeline expansion projects. With the upgrading of production lines and the increase of production capacity, their production and manufacturing capabilities will be further increased. At the same time, Baiyang Pharmaceutical is also closely cooperating with national research institutions to promote the innovation process of more high-end preparations, modern traditional Chinese medicine, and natural medicine original research products.

In the future, Baiyang Pharmaceutical will seize the dual opportunities of "innovation" and "creation" in China's pharmaceutical industry, and continuously stimulate the endogenous driving force and development vitality of the health industry with the development pattern of modern traditional Chinese medicine and high-end formulated drugs. Through technological innovation, it will optimize medical scenarios and make greater contributions to human health.